To date, there is still no approved anti-dengue agent to treat dengue infection in the market. Although the only licensed dengue vaccine, Dengvaxia is available, its protective efficacy against serotypes 1 and 2 of dengue virus was reported to be lower than serotypes 3 and 4. Moreover, according to WHO, the risk of being hospitalized and having severe dengue increased in seronegative individuals after they received Dengvaxia vaccination. Nevertheless, various studies had been carried out in search of dengue virus inhibitors. These studies focused on the structural (C, prM, E) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) of dengue virus as well as host factors as drug targets. Hence, this article provides an overall up-to-date review of the discovery of dengue virus inhibitors that are only targeting the structural and non-structural viral proteins as drug targets.

迄今为止，市场上仍没有批准的抗登革热剂来治疗登革热感染。尽管可以使用唯一获得许可的登革热疫苗Dengvaxia，但据报道其对1型和2型登革热病毒的保护作用低于3型和4型登革热。此外，根据WHO的说法，在美国住院和罹患严重登革热的风险有所增加。血清疫苗接种后，血清阴性的人。然而，已经进行了各种研究以寻找登革热病毒抑制剂。这些研究集中于登革病毒的结构蛋白（C，prM，E）和非结构蛋白（NS1，NS2A，NS2B，NS3，NS4A，NS4B和NS5）以及作为药物靶标的宿主因子。因此，